Big Buttons

• CALL TO ACTION: Tell FDA to deny drugmakers’ request

  Drugmakers are urging FDA to prohibit compounded GLP-1s. FDA needs to hear from you and your patients NOW! read more →

• APC to FDA: Just say no to Lilly

  This week APC's lawyers sent a formal comment to the FDA about Eli Lilly’s request that tirzepatide be added to the Demonstrably Difficult to Compound list. read more →

• California BOP sends proposed compounding regs to comment period

  The California State Board of Pharmacy decided to move the modified proposed sterile compounding regulations forward to a 30-day comment period. read more →

• Checking in on the post-Chevron fallout

  What’s happened in the world of federal regulation since the end of Chevron? read more →

• Hi, Noom!

  Welcome to our newest Bronze-level Corporate Patron, Noom! read more →

• PFMs can get 2.5% credit card processing

  A new benefit for APC’s Pharmacy/Facility Members: They may be able to cut their credit card processing fees to just 2.5% – 2.8%. read more →

• Phoenix compounders, rise!

  The latest of APC’s new regional meetings — CompoundED UpDATE — is coming to the Phoenix area December 5. read more →

• APC election results: directors and bylaws

  See the results of APC's elections, including four new directors and several changes to our bylaws. read more →

More News

NPR’s Sydney Lupkin continues to achieve balance and accuracy in her reporting on compounding, and we’re grateful for it. Her article this weekfocused on what will happen to compounded GLP-1s when Novo and Lilly finally get things under control and the shortage ends, and APC’s Scott Brunner is quoted. She also wrote an article back in June that provided solid advice to patients considering compounded GLP-1s. We briefed her for both.

The Washington Post’s Daniel Gilbert and Teddy Amenabar gave compounding a fair shake in their article on compounded GLP-1s last week, and a KFF Health News article by Arthur Allen also did a pretty good job being balanced about the issue (with the exception of the illustration). Both Gilbert and Allen have toured compounding pharmacies; APC also briefed them several times for their respective stories.

We’re out there, working with the press to fight misinformation about compounding, especially with GLP-1s. And with several reporters at least, our message is starting to get through.